THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND
CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE
BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES

Baptist University, Hong Kong
24 – 26 January 2013

LIST OF PARTICIPANTS

Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan

Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America

Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy

Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America

Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia

Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America

Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China

Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa

Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America
Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway

Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici et Farmaceutici, Novartis Vaccines, Siena, Italy

Dr Carlos Diaz Granados, Clinical Team Leader, Director Clinical Development, Sanofi Pasteur, United States of America

Dr Katherine Donegan, Medicines and Healthcare products Regulatory Agency, London, United Kingdom

Dr Emelia Dwiyanti Wibowo, Head of Production, Indonesia

Dr Othmar Engelhardt, Principal Scientist, National Institute for Biological Standards and Control, Health Protection Agency, Potters Bar, Hertfordshire, United Kingdom

Professor Janet Englund, Professor at University of Washington, Infectious Disease Program, University of Washington, Seattle, United States of America

Dr Marina Erofeeva, Head of the Laboratory of Trials of Novel Remedies for Antiviral Protection Research, Institute of Influenza, St Petersburg, Russia

Dr Jose Esparza, Senior Advisor on HIV Vaccines, HIV, TB & Reproductive Health, Global Health Program, The Bill & Melinda Gates Foundation, Seattle, Washington D.C, United States of America

Dr Susanna Esposito, Department of Pathophysiology and Transplantation, Università degli Studi di Milan, Milano, Italy

Professor Sarah Gilbert, Professor of Vaccinology, The Jenner Institute, Oxford, United Kingdom

Dr Marc Girard, Consultant, Lyon, France

Dr Hugo Gomes da Silva, Global Medical Lead, HIV & Influenza, GSK, Wavre, Belgium

Ms Tanya Gottlieb, Business Development, Biond Vax Pharmaceuticals Ltd, Nes Ziona, Israel

Dr Yi Guan, The Univerisity of Hong Kong, Hong Kong, China

Professor Frederick Hayden, Influenza Research Coordinator, International activities-Science Funding, The Wellcome Trust, London, United Kingdom

Dr Guillermo Herrera-Taracena, GMA Leader for Infectious Diseases and Vaccines, Johnson & Johnson, New Brunswick, United States of America

Dr Baoying Huang, Institute for Viral Disease Control and Prevention, Xuan Wu Qu, China
Dr Baoying Hunag, Institute for Viral Disease Control and Prevention, Xuan-WU Qu, China

Dr Robert Huebner, Acting Director - Influenza Division, Biomedical Advanced Research & Development Authority (BARDA), US Department of Health and Human Services (HHS), Washington, United States of America

Dr David Hui, Director, Stanley Ho Center for Emerging Infectious Diseases, Hong Kong, China

Professor Margaret IP, Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China

Dr Irina Isakova-Sivak, Department of Virology, Institute of Experimental Medicine, St. Petersburg, Russia

Dr Mark Jit, Mathematical Modeller, Modelling and Economics Unit, Health Protection Agency, London, United Kingdom

Dr Jacqueline M. Katz, Epidemiology and Prevention Branch, Influenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America

Dr Anne Kelso, Director, WHO Collaborating Centre for Reference & Research on Influenza, Melbourne, Victoria, Australia

Dr Soo In Kim, Green Cross Corporation, Gyeonggi-do, Republic of Korea

Dr Otfried Kistner, Senior Director, Virology/Viral Vaccines, Biomedical Research Center, Baxter BioScience, Orth/Donau, Austria

Dr Harry Kleanthous, Head, Discovery Research, North America, Sanofi Pasteur Biologics Co., Cambridge, United States of America

Ms Janna Klein Bretler, Preparedness and Response Unit, Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM) Bilthoven, Netherlands

Dr Florian Krammer, Department of Microbiology, Mount Sinai School of Medicine, New York, United States of America

Professor Dominc Man-Kit Lam, Chairman, World Eye Organization, Hong Kong, China

Dr Fong Lam, Baylor College of Medicine, Pediatric Crucial Care, Texas Children’s Hospital, Houston, Texas, United States of America

Ms Nathalie Landry, Vice-President, Product Development, Research & Development, Medicago R & D Inc. Quebec, Canada

Dr Vernon Lee, Adjunct Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore
Mr Bertrand Lepine, President Fab'entech, Fab'entech, Lyon, France

Dr Xiaoyu Liu, Institute for Viral Disease Control and Prevention, China CDC, Beijing, China

Dr Xiuhua Lu, Centers for Diseases Control and Prevention, Atlanta, United States of America

Professor Arnold Monto, The Thomas Francis Jr. Professor, Epidemiology, The University of Michigan School of Public Health, Ann Arbor, United States of America

Professor Antony E. Nelson, Professor, Department of Paediatrics - Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China

Dr Kathleen Neuzil, Programme Leader Vaccine Access and Delivery (VAD) Program, Program for Appropriate Technology in Health, Seattle, United States of America

Dr Huan H. Nguyen, Principal Investigator, International Vaccine Institute, Kwanak-gu, Seoul, Republic of Korea

Professor Thu Van Nguyen, General Director, The Company for Vaccine and Biologicals Production No.1, National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam

Professor Angus Nicoll, Senior Expert, Influenza Coordination, European Centre for Disease Prevention and Control, Stockholm, Sweden

Dr Hanna Nohynek, Academy Research Fellow, ARIVAC Coordinator, Vaccine Research, National Institute for Health and Welfare, Helsinki, Finland

Dr Joerdis J. Ott, Consultant, Vevey, Switzerland

Professor Malik Peiris, The University of Hong Kong, Hong Kong, China

Dr Yuri Pervikov, Consultant, Geneva, Switzerland

Professor Punnee Pitisuttithum, Clinical Infectious Disease Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Dr Leo Poon, State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, China

Dr Alexander R Precioso, Medical Director, Clinical Trials, Clinical Trials Division, Instituto Butantan, São Paulo, Brazil

Dr Paul Radspinner, President & CEO, FluGen Inc., Madison, United States of America

Dr Eleanor Ramos, Chief Medical Officer, Theraclone Sciences, Seattle, United States of America

Mr Bambang Heriyanto Rasbun, Production Manager, Bio Farma, Bandung, Indonesia
Professor Gustaaf Rimmelzwaan, Department of Virology, Erasmus Medical Center (MC), Rotterdam, Netherlands

Dr Theodore Ross, Associate Professor, Center for Vaccine Research, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Professor Li-Ruan, Professor of Department, Biotech Center for Viral Disease Emergency, Chinese Center for Disease Control and Prevention, Beijing, China

Professor Larisa Rudenko, Head, Department of Virology, Institute of Experimental Medicine, St. Petersburg, Russia

Dr Rachelle Salomon, Program Officer, Influenza SARS & Related Viral Respiratory Diseases Section, Respiratory Diseases Branch, National Institute of Allergy and Infectious Diseases (NIAID/NIH), Bethesda, United States of America

Dr Sandrine Sampson, Sanofi Pasteur, Lyon, France

Dr Vivek Shinde, GlaxoSmithKline Biologicals SA, Rixensart, Belgium

Dr Kunihiko Shinna, Director Global Vaccine Business, Astellas Pharma Inc., Tokyo, Japan

Dr Yuelong Shu, Director, WHO Collaborating Center for Reference and Research on Influenza, China Center for Disease Control and Prevention, Beijing, China

Dr Mark Simmerman, Regional Director, Epidemiology, Sanofi Pasteur, Bangkok, Thailand

Dr Marina Stukova, Research Institute of Influenza, St Petersburg, Russia

Dr Kanta Subbarao, Senior Investigator, Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, United States of America

Dr Masato Tashiro, Director, Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan

Professor Alain Townsend, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom

Dr Theodore F. Tsai, Sr. VP, Scientific Affairs, Novartis Vaccines, Cambridge, United States of America

Dr Vadim Tsvetnitsky, Influenza Project Leader, Vaccine Development Global Program, PATH, Washington DC, United States of America

Dr Sophie Valkenburg, The University of Hong Kong, Hong Kong, China
Professor Timo Vesikari, Vaccine Research Center, University of Tampere School of Medicine, Tampere, Finland

Dr Tinh Tuan Viet, The Company for Vaccines and Biological Production No 1 (VABIOTECH), Ha Noi, Viet Nam

Dr Ralf Wagner, Section Viral vaccines, Paul-Ehrlich-Institut, Langen, Germany

Dr Niteen Wairagkar, Senior Program Officer, Infectuous Diseases, Global Health Program, The Bill and Melinda Gates Foundation, Seattle, United States of America

Dr Guiqin Wang, Research Assistant of Dr Paul Zhou, Shanghai Institute for Biological Sciences, Shanghai, China

Dr Wenling Wang, Institute for Viral Disease Control and Prevention, Beijing, China

Professor Ricky Wong, Associate Dean, Faculty of Science, Hong Kong Baptist University, Hong Kong, China

Dr Fei Xu, President Assistant, Project Director, Changchun BCHT Biotechnology Co., Jilin, China

Professor Yuhong Xu, School of Pharmacy, Shanghai Jiaotong University, Shanghai, China

Dr Hui Xue, Head of clinical trails, Changchun BCHT Biotechnology Co, Jilin, China

Dr Maria Zambon, Head of Respiratory Virus Unit, Deputy Director ERNVL, Enteric, Respiratory & Neurological Virus Laboratory, Health Protection Agency, London, United Kingdom

Dr Zhiqing Zhang, Institute for Viral Disease Control and Prevention, Beijing, China

Mr Fan Zhou, PHD student of Dr Paul Zhou, Shanghai Institute for Biological Sciences, Shanghai, China

Dr Paul Zhou, Principal Investigator, Antiviral Immunity and Genetic Therapy Unit, Shanghai Institute for Biological Sciences, Shanghai, China
WHO/HQ SECRETARIAT

Dr Julia Fitzner, HQ/HIP Influenza, Hepatitis and PIP Framework, Health Security and Environment (HSE), WHO/HQ, Geneva, Switzerland

Dr Joachim Hombach, Senior Adviser, HQ/IVR Initiative for Vaccine Research, Family, Women's and Children's Health (FWC), WHO HQ, Geneva, Switzerland

Dr Philipp Lambach, HQ/QSS Quality, Safety and Standards, Family, Women's and Children's Health (FWC), WHO HQ, Geneva, Switzerland

Mrs Jacqueline Lee Endt, HQ/IVR, Initiative for Vaccine Research, Family, Women's and Children's Health (FWC), WHO HQ, Geneva, Switzerland

Dr Anthony Mounts, HQ/HIP Influenza, Hepatitis and PIP Framework, Health Security and Environment (HSE), WHO HQ, Geneva, Switzerland

Ms Erin Sparrow, HQ/IEA Technology Transfer initiative, Health Systems and Innovation (HIS), WHO HQ, Geneva, Switzerland

Dr John Siu Lun Tam, HQ/IVR, Initiative for Vaccine Research, Family, Women's and Children's Health (FWC), WHO HQ, Geneva, Switzerland

Dr Wenqing Zhang, HQ/HIP Influenza, Hepatitis and PIP Framework, Health Security and Environment (HSE), WHO/HQ, Geneva, Switzerland